JP2020504741A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020504741A5 JP2020504741A5 JP2019534245A JP2019534245A JP2020504741A5 JP 2020504741 A5 JP2020504741 A5 JP 2020504741A5 JP 2019534245 A JP2019534245 A JP 2019534245A JP 2019534245 A JP2019534245 A JP 2019534245A JP 2020504741 A5 JP2020504741 A5 JP 2020504741A5
- Authority
- JP
- Japan
- Prior art keywords
- alkyl
- optionally substituted
- group
- substituted
- ulm
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 0 CC(*)N(*)C(C(*)NC(C(C)N)=O)=O Chemical compound CC(*)N(*)C(C(*)NC(C(C)N)=O)=O 0.000 description 48
- DERXELLTUOVDQH-UHFFFAOYSA-N CN(C1)CC1F Chemical compound CN(C1)CC1F DERXELLTUOVDQH-UHFFFAOYSA-N 0.000 description 4
- PQNFLJBBNBOBRQ-UHFFFAOYSA-N C1Cc2ccccc2C1 Chemical compound C1Cc2ccccc2C1 PQNFLJBBNBOBRQ-UHFFFAOYSA-N 0.000 description 2
- IXHFNEAFAWRVCF-UHFFFAOYSA-N CC(C)C(NC)=O Chemical compound CC(C)C(NC)=O IXHFNEAFAWRVCF-UHFFFAOYSA-N 0.000 description 2
- ZAMXVCJJAQXCBT-UHFFFAOYSA-N CN(CC1)CC1F Chemical compound CN(CC1)CC1F ZAMXVCJJAQXCBT-UHFFFAOYSA-N 0.000 description 2
- YNZOOJLMTULUQT-XNWIYYODSA-N CN(CCC1)C1C(C1)N(C)C[C@@H]1F Chemical compound CN(CCC1)C1C(C1)N(C)C[C@@H]1F YNZOOJLMTULUQT-XNWIYYODSA-N 0.000 description 2
- VDOLWAQYIDIFME-WHFBIAKZSA-N CN(C[C@@H]1O)C[C@@H]1F Chemical compound CN(C[C@@H]1O)C[C@@H]1F VDOLWAQYIDIFME-WHFBIAKZSA-N 0.000 description 2
- SHAHSPDXKLHDNO-NKVNRFPTSA-N C[C@H](C[C@H]1F)C1C1N(C)CCCC1 Chemical compound C[C@H](C[C@H]1F)C1C1N(C)CCCC1 SHAHSPDXKLHDNO-NKVNRFPTSA-N 0.000 description 2
- KDSAXEOLUPBMBT-UHFFFAOYSA-N C=[Br]c1cc(c(C(c(c(F)ccc2NS(CC(CO)O)(=O)=O)c2F)=O)c[nH]2)c2nc1 Chemical compound C=[Br]c1cc(c(C(c(c(F)ccc2NS(CC(CO)O)(=O)=O)c2F)=O)c[nH]2)c2nc1 KDSAXEOLUPBMBT-UHFFFAOYSA-N 0.000 description 1
- RCOAYXFWTLIZRE-UHFFFAOYSA-N CC(C)(C)OC(CN1CCC(CN(CC2)CCN2c(cc2)ccc2Br)CC1)=O Chemical compound CC(C)(C)OC(CN1CCC(CN(CC2)CCN2c(cc2)ccc2Br)CC1)=O RCOAYXFWTLIZRE-UHFFFAOYSA-N 0.000 description 1
- ZTAZUQNGWKMQMQ-UHFFFAOYSA-N CC(C)(C)OC(N(C1)CC1Oc(cc1)ccc1-[n](cc1Br)nc1-c1ccncc1)=O Chemical compound CC(C)(C)OC(N(C1)CC1Oc(cc1)ccc1-[n](cc1Br)nc1-c1ccncc1)=O ZTAZUQNGWKMQMQ-UHFFFAOYSA-N 0.000 description 1
- AGHUJPNOYUMQSV-UHFFFAOYSA-N CC(C)(C)OC(N(CC1)CCC1N(CC1)CCC1[n](cc1-c(cc2)cc(CC3)c2C3=O)nc1-c1ccncc1)=O Chemical compound CC(C)(C)OC(N(CC1)CCC1N(CC1)CCC1[n](cc1-c(cc2)cc(CC3)c2C3=O)nc1-c1ccncc1)=O AGHUJPNOYUMQSV-UHFFFAOYSA-N 0.000 description 1
- HFJDGWPENBIHKK-UHFFFAOYSA-N CC(C)(C)OC(N(CC1)CCN1c1cccc2c1C1OC1N(C(CCC(N1)=O)C1=O)C2=O)=O Chemical compound CC(C)(C)OC(N(CC1)CCN1c1cccc2c1C1OC1N(C(CCC(N1)=O)C1=O)C2=O)=O HFJDGWPENBIHKK-UHFFFAOYSA-N 0.000 description 1
- KARHZPCIVJWKRD-MUUNZHRXSA-N CC(C)(C)OC(N1CCN(CCOCCOc(cc2)ccc2-c2cc(c(C(c(c(F)c(cc3)NCCN(CC4)C[C@@H]4F)c3F)=O)c[nH]3)c3nc2)CC1)=O Chemical compound CC(C)(C)OC(N1CCN(CCOCCOc(cc2)ccc2-c2cc(c(C(c(c(F)c(cc3)NCCN(CC4)C[C@@H]4F)c3F)=O)c[nH]3)c3nc2)CC1)=O KARHZPCIVJWKRD-MUUNZHRXSA-N 0.000 description 1
- VTKNFMYABFTAQP-ZFGGDYGUSA-N CC(C)(C)[C@@H](C(N(C[C@@H](C1)O)[C@@H]1C(NCc(cc1)ccc1-c1c(C)nc[s]1)=O)=O)NC(CNC(OC(C)(C)C)=O)=O Chemical compound CC(C)(C)[C@@H](C(N(C[C@@H](C1)O)[C@@H]1C(NCc(cc1)ccc1-c1c(C)nc[s]1)=O)=O)NC(CNC(OC(C)(C)C)=O)=O VTKNFMYABFTAQP-ZFGGDYGUSA-N 0.000 description 1
- MGFBAMQBZTVJRS-UJSFRCSHSA-N CC(C)(C)[C@@H](C(N(C[C@@H](C1)O)[C@@H]1C(NCc(cc1)ccc1-c1c(C)nc[s]1)=O)=O)NC(COCCCN(CC1)CCN1C(CC1)=CC=C1c1cc(c(C(c(c(F)ccc2NS(N(CC3)C[C@@H]3F)(=O)=O)c2F)=O)c[nH]2)c2nc1)=O Chemical compound CC(C)(C)[C@@H](C(N(C[C@@H](C1)O)[C@@H]1C(NCc(cc1)ccc1-c1c(C)nc[s]1)=O)=O)NC(COCCCN(CC1)CCN1C(CC1)=CC=C1c1cc(c(C(c(c(F)ccc2NS(N(CC3)C[C@@H]3F)(=O)=O)c2F)=O)c[nH]2)c2nc1)=O MGFBAMQBZTVJRS-UJSFRCSHSA-N 0.000 description 1
- SRGDAQPTGJKAMK-RUDCESOPSA-N CC(C)(C)[C@@H](C(N(C[C@@H](C1)O)[C@@H]1C(NCc(cc1)ccc1-c1c(C)nc[s]1)=O)=O)NC(COCCOc(cc1)ccc1-[n](cc1-c(cc2CC3)ccc2C3=O)nc1-c1ccncc1)=O Chemical compound CC(C)(C)[C@@H](C(N(C[C@@H](C1)O)[C@@H]1C(NCc(cc1)ccc1-c1c(C)nc[s]1)=O)=O)NC(COCCOc(cc1)ccc1-[n](cc1-c(cc2CC3)ccc2C3=O)nc1-c1ccncc1)=O SRGDAQPTGJKAMK-RUDCESOPSA-N 0.000 description 1
- NEJPPXZUWGFBDL-HTCXSVJXSA-N CC(C)C(C(N(C[C@@H](C1)O)[C@@H]1C(N[C@@H](C)c(cc1)ccc1-c1cnc[o]1)=O)=O)c1cc(C)n[o]1 Chemical compound CC(C)C(C(N(C[C@@H](C1)O)[C@@H]1C(N[C@@H](C)c(cc1)ccc1-c1cnc[o]1)=O)=O)c1cc(C)n[o]1 NEJPPXZUWGFBDL-HTCXSVJXSA-N 0.000 description 1
- SXFWBOTXORQGJN-UHFFFAOYSA-N CC(C)CCC(NC)=O Chemical compound CC(C)CCC(NC)=O SXFWBOTXORQGJN-UHFFFAOYSA-N 0.000 description 1
- IYDMGGPKSVWQRT-XZWHSSHBSA-N CC(C)Oc(cc(cc1)OC)c1C(N([C@@H]1c(cc2)ccc2Cl)C(N(CC2)CCN2C(C)=O)=O)=N[C@H]1c(cc1)ccc1Cl Chemical compound CC(C)Oc(cc(cc1)OC)c1C(N([C@@H]1c(cc2)ccc2Cl)C(N(CC2)CCN2C(C)=O)=O)=N[C@H]1c(cc1)ccc1Cl IYDMGGPKSVWQRT-XZWHSSHBSA-N 0.000 description 1
- CWWBCISTWBLCMI-CGYACHGYSA-N CC(C)[C@@H](C(N(C[C@@H](C1)O)C1(C)C(NCc(cc1)ccc1-c1c(C)nc[s]1)=O)=O)N(Cc1ccccc11)C1=O Chemical compound CC(C)[C@@H](C(N(C[C@@H](C1)O)C1(C)C(NCc(cc1)ccc1-c1c(C)nc[s]1)=O)=O)N(Cc1ccccc11)C1=O CWWBCISTWBLCMI-CGYACHGYSA-N 0.000 description 1
- FEWHVHJXHQNNTR-LFRRGIFHSA-N CC(C)[C@@H](C(N(C[C@@H](C1)O)C1(C)C(NCc(cc1)ccc1C1=C(C/[O]=C(\c2ccccc2C2)/N2[C@@H](C(C)C)C(N(C[C@@H](C2)O)C2(C)C(NCc(cc2)ccc2C2=C(C/[O]=C(\c3c(C4)cccc3)/N4[C@@H](C(C)C)C(N(C[C@@H](C3)O)C3(C)C(NCc(cc3)ccc3C3=C(C)NCS3)=O)=O)NCS2)=O)=O)NCS1)=O)=O)N(Cc1ccccc11)C1=O Chemical compound CC(C)[C@@H](C(N(C[C@@H](C1)O)C1(C)C(NCc(cc1)ccc1C1=C(C/[O]=C(\c2ccccc2C2)/N2[C@@H](C(C)C)C(N(C[C@@H](C2)O)C2(C)C(NCc(cc2)ccc2C2=C(C/[O]=C(\c3c(C4)cccc3)/N4[C@@H](C(C)C)C(N(C[C@@H](C3)O)C3(C)C(NCc(cc3)ccc3C3=C(C)NCS3)=O)=O)NCS2)=O)=O)NCS1)=O)=O)N(Cc1ccccc11)C1=O FEWHVHJXHQNNTR-LFRRGIFHSA-N 0.000 description 1
- VBGCXCMUKOYHJF-RZUBCFFCSA-N CC(C)[C@@H](C(N(C[C@@H](C1)O)[C@@H]1C(NCc(cc1)ccc1-c1c(C)nc[s]1)=O)=O)c1cc(C)n[s]1 Chemical compound CC(C)[C@@H](C(N(C[C@@H](C1)O)[C@@H]1C(NCc(cc1)ccc1-c1c(C)nc[s]1)=O)=O)c1cc(C)n[s]1 VBGCXCMUKOYHJF-RZUBCFFCSA-N 0.000 description 1
- YQOGFIVOLUHWKC-BAGYTPMASA-N CC(C)[C@@H](C(N(C[C@@H](C1)O)[C@@H]1C(NCc(cc1)ccc1-c1c(C)nc[s]1)=O)=O)c1n[nH]c(C)c1 Chemical compound CC(C)[C@@H](C(N(C[C@@H](C1)O)[C@@H]1C(NCc(cc1)ccc1-c1c(C)nc[s]1)=O)=O)c1n[nH]c(C)c1 YQOGFIVOLUHWKC-BAGYTPMASA-N 0.000 description 1
- GFRBMXSURJKHGR-HSALFYBXSA-N CC(C)[C@@H](C(N(C[C@@H](C1)O)[C@@H]1C(NCc(cc1)ccc1-c1c(C)nc[s]1)=O)=O)c1nc(C)n[s]1 Chemical compound CC(C)[C@@H](C(N(C[C@@H](C1)O)[C@@H]1C(NCc(cc1)ccc1-c1c(C)nc[s]1)=O)=O)c1nc(C)n[s]1 GFRBMXSURJKHGR-HSALFYBXSA-N 0.000 description 1
- IHDWHNABLZYBIH-CZHRTVMISA-N CC(C)[C@@H](C(N(C[C@@H](C1)O)[C@@H]1C(NCc(cc1)ccc1-c1c(C)nc[s]1)=O)=O)c1nnc(C)[n]1Cc1c(-c2ccc(CNC([C@H](C[C@H](C3)O)N3C([C@H](C(C)C)c3nc(C)n[o]3)=O)=O)cc2)[s]cn1 Chemical compound CC(C)[C@@H](C(N(C[C@@H](C1)O)[C@@H]1C(NCc(cc1)ccc1-c1c(C)nc[s]1)=O)=O)c1nnc(C)[n]1Cc1c(-c2ccc(CNC([C@H](C[C@H](C3)O)N3C([C@H](C(C)C)c3nc(C)n[o]3)=O)=O)cc2)[s]cn1 IHDWHNABLZYBIH-CZHRTVMISA-N 0.000 description 1
- NMQOREDOOXJWIK-HSALFYBXSA-N CC(C)[C@@H](C(N(C[C@@H](C1)O)[C@@H]1C(NCc(cc1)ccc1-c1c(C)nc[s]1)=O)=O)c1nnc(C)[o]1 Chemical compound CC(C)[C@@H](C(N(C[C@@H](C1)O)[C@@H]1C(NCc(cc1)ccc1-c1c(C)nc[s]1)=O)=O)c1nnc(C)[o]1 NMQOREDOOXJWIK-HSALFYBXSA-N 0.000 description 1
- UAOHBORKFLZBPO-HSALFYBXSA-N CC(C)[C@@H](C(N(C[C@@H](C1)O)[C@@H]1C(NCc(cc1)ccc1-c1c(C)nc[s]1)=O)=O)c1nnc(C)[s]1 Chemical compound CC(C)[C@@H](C(N(C[C@@H](C1)O)[C@@H]1C(NCc(cc1)ccc1-c1c(C)nc[s]1)=O)=O)c1nnc(C)[s]1 UAOHBORKFLZBPO-HSALFYBXSA-N 0.000 description 1
- YYSFFVIJGUQALQ-BAGYTPMASA-N CC(C)[C@@H](C(N(C[C@@H](C1)O)[C@@H]1C(NCc(cc1)ccc1C1=C(C)NCS1)=O)=O)c1n[o]c(C)c1 Chemical compound CC(C)[C@@H](C(N(C[C@@H](C1)O)[C@@H]1C(NCc(cc1)ccc1C1=C(C)NCS1)=O)=O)c1n[o]c(C)c1 YYSFFVIJGUQALQ-BAGYTPMASA-N 0.000 description 1
- GJGXQAODWZABIH-DMTNHVFBSA-N CC(C)[C@@H](CN(C[C@@H](C1)O)[C@@H]1C(NCc(cc1)ccc1-c1c(C)nc[s]1)=N)N(C=C1C2=CC=CC1)C2=O Chemical compound CC(C)[C@@H](CN(C[C@@H](C1)O)[C@@H]1C(NCc(cc1)ccc1-c1c(C)nc[s]1)=N)N(C=C1C2=CC=CC1)C2=O GJGXQAODWZABIH-DMTNHVFBSA-N 0.000 description 1
- YKABBFAFVRCVPP-AULYBMBSSA-N CC(CN(CC1)CCC1O[C@H](C1)C[C@@H]1NC)=O Chemical compound CC(CN(CC1)CCC1O[C@H](C1)C[C@@H]1NC)=O YKABBFAFVRCVPP-AULYBMBSSA-N 0.000 description 1
- UZOFELREXGAFOI-UHFFFAOYSA-N CC1CCNCC1 Chemical compound CC1CCNCC1 UZOFELREXGAFOI-UHFFFAOYSA-N 0.000 description 1
- GCEWJCVKPTZCRU-UHFFFAOYSA-N CCC1OC1NC Chemical compound CCC1OC1NC GCEWJCVKPTZCRU-UHFFFAOYSA-N 0.000 description 1
- QKGZBDBAWVAAKZ-UHFFFAOYSA-N CCCC(CCC)CCC(NC)=O Chemical compound CCCC(CCC)CCC(NC)=O QKGZBDBAWVAAKZ-UHFFFAOYSA-N 0.000 description 1
- QNEGXSQWCRRYSN-QPJOQSLLSA-N CCCS(Nc(c(F)c1-[n](cc2/C(/C=N)=C/N)c(cc3)c2nc3N(C)C2CCNCC2)ccc1F)(=O)=O Chemical compound CCCS(Nc(c(F)c1-[n](cc2/C(/C=N)=C/N)c(cc3)c2nc3N(C)C2CCNCC2)ccc1F)(=O)=O QNEGXSQWCRRYSN-QPJOQSLLSA-N 0.000 description 1
- JNSRQBZQGWFBKE-UHFFFAOYSA-N CCCS(Nc(ccc(F)c1-[n]2c3ccc(N(C)C(CC4)CCN4c4cccc5c4COCN(C(CCC(N4)=O)C4=O)C5=O)nc3c(-c3cncnc3)c2)c1F)(=O)=O Chemical compound CCCS(Nc(ccc(F)c1-[n]2c3ccc(N(C)C(CC4)CCN4c4cccc5c4COCN(C(CCC(N4)=O)C4=O)C5=O)nc3c(-c3cncnc3)c2)c1F)(=O)=O JNSRQBZQGWFBKE-UHFFFAOYSA-N 0.000 description 1
- DWLFNIVXWUHBJQ-UHFFFAOYSA-N CCCS(Nc(ccc(F)c1-[n]2c3ccc(N(C)C4CCNCC4)nc3c(-c3cncnc3)c2)c1F)(=O)=O Chemical compound CCCS(Nc(ccc(F)c1-[n]2c3ccc(N(C)C4CCNCC4)nc3c(-c3cncnc3)c2)c1F)(=O)=O DWLFNIVXWUHBJQ-UHFFFAOYSA-N 0.000 description 1
- QXMBWAUFPOAKNN-OQKACKPTSA-N CCCS(Nc(ccc(F)c1C(c(c2c3)c[nH]c2ncc3N(CC2)CCN2C(CCCC(N[C@@H](C(C)(C)C)C(N(C[C@@H](C2)O)[C@@H]2C(NCc(cc2)ccc2-c2c(C)nc[s]2)=O)=O)=O)=O)=O)c1F)(=O)=O Chemical compound CCCS(Nc(ccc(F)c1C(c(c2c3)c[nH]c2ncc3N(CC2)CCN2C(CCCC(N[C@@H](C(C)(C)C)C(N(C[C@@H](C2)O)[C@@H]2C(NCc(cc2)ccc2-c2c(C)nc[s]2)=O)=O)=O)=O)=O)c1F)(=O)=O QXMBWAUFPOAKNN-OQKACKPTSA-N 0.000 description 1
- RTRZHLJEMYASNC-HJZXASKDSA-N CN(C(CCC1N(C(c(cc2)c3cc2N(CC2)CCN2c(cc2)ccc2-[n](cc2-c(cc4)cc(CC5)c4/C5=N/O)nc2-c2ccncc2)=O)C3=O)=O)C1=O Chemical compound CN(C(CCC1N(C(c(cc2)c3cc2N(CC2)CCN2c(cc2)ccc2-[n](cc2-c(cc4)cc(CC5)c4/C5=N/O)nc2-c2ccncc2)=O)C3=O)=O)C1=O RTRZHLJEMYASNC-HJZXASKDSA-N 0.000 description 1
- KDUOPPMIWCFSEU-UHFFFAOYSA-N CN(C(CCC1N(C(c(cc2)c3cc2NCCNc(cc2)ccc2-[n](cc2-c(cc4)cc(CC5)c4C5=O)nc2-c2ccncc2)=O)C3=O)=O)C1=O Chemical compound CN(C(CCC1N(C(c(cc2)c3cc2NCCNc(cc2)ccc2-[n](cc2-c(cc4)cc(CC5)c4C5=O)nc2-c2ccncc2)=O)C3=O)=O)C1=O KDUOPPMIWCFSEU-UHFFFAOYSA-N 0.000 description 1
- VDOLWAQYIDIFME-UHFFFAOYSA-N CN(CC1O)CC1F Chemical compound CN(CC1O)CC1F VDOLWAQYIDIFME-UHFFFAOYSA-N 0.000 description 1
- LCQASUWGXZDLLK-FXLOMAGBSA-N CN(CCOc(cc1)ccc1-[n](cc1-c(cc2)cc(CC3)c2/C3=N/O)nc1-c1ccncc1)c(cc1)cc(C(N2C(CCC(N3)=O)C3=O)=O)c1C2=O Chemical compound CN(CCOc(cc1)ccc1-[n](cc1-c(cc2)cc(CC3)c2/C3=N/O)nc1-c1ccncc1)c(cc1)cc(C(N2C(CCC(N3)=O)C3=O)=O)c1C2=O LCQASUWGXZDLLK-FXLOMAGBSA-N 0.000 description 1
- VDOLWAQYIDIFME-BRJRFNKRSA-N CN(C[C@H]1O)CC1F Chemical compound CN(C[C@H]1O)CC1F VDOLWAQYIDIFME-BRJRFNKRSA-N 0.000 description 1
- LARRZJQWINEIFU-UHFFFAOYSA-N CN1CC(CCN2CCNCC2)CC1 Chemical compound CN1CC(CCN2CCNCC2)CC1 LARRZJQWINEIFU-UHFFFAOYSA-N 0.000 description 1
- PVOAHINGSUIXLS-UHFFFAOYSA-N CN1CCNCC1 Chemical compound CN1CCNCC1 PVOAHINGSUIXLS-UHFFFAOYSA-N 0.000 description 1
- UPIHZCDTQBTGHI-UHFFFAOYSA-N CNCCOc(cc1)ccc1-[n](cc1Br)nc1-c1ccncc1 Chemical compound CNCCOc(cc1)ccc1-[n](cc1Br)nc1-c1ccncc1 UPIHZCDTQBTGHI-UHFFFAOYSA-N 0.000 description 1
- DYGHSFRVQSBDJP-RXMQYKEDSA-N CS(N(CC1)C[C@@H]1F)(=O)=O Chemical compound CS(N(CC1)C[C@@H]1F)(=O)=O DYGHSFRVQSBDJP-RXMQYKEDSA-N 0.000 description 1
- UATHGXSVZBAWEK-JFHPQLLQSA-N C[C@@H](C(N[C@@H](C)C(N(C1)[C@H](CN(CCc2ccccc2)C2)[C@H]2[C@@H]1OCCO[C@H](C1)C(CN(CCC2=CCCC=C2)C2)[C@@H]2N1C([C@H](COC(CCC(OC)=O)=O)NC([C@H](N)NC)=O)=O)=O)=O)NC Chemical compound C[C@@H](C(N[C@@H](C)C(N(C1)[C@H](CN(CCc2ccccc2)C2)[C@H]2[C@@H]1OCCO[C@H](C1)C(CN(CCC2=CCCC=C2)C2)[C@@H]2N1C([C@H](COC(CCC(OC)=O)=O)NC([C@H](N)NC)=O)=O)=O)=O)NC UATHGXSVZBAWEK-JFHPQLLQSA-N 0.000 description 1
- IBBHIZXRMBKKII-IYNDAXALSA-N C[C@@H](C(N[C@@H](C1CCCCC1)C(N(CC[C@@H]1C)[C@@H]1C(Nc1cc(C)n[n]1-c1ccccc1)=O)=O)=O)NC Chemical compound C[C@@H](C(N[C@@H](C1CCCCC1)C(N(CC[C@@H]1C)[C@@H]1C(Nc1cc(C)n[n]1-c1ccccc1)=O)=O)=O)NC IBBHIZXRMBKKII-IYNDAXALSA-N 0.000 description 1
- AADMRSQDLRYQQU-UHFFFAOYSA-N Cc1cc(CCCCCCN2CCN(C)CC2)n[o]1 Chemical compound Cc1cc(CCCCCCN2CCN(C)CC2)n[o]1 AADMRSQDLRYQQU-UHFFFAOYSA-N 0.000 description 1
- NKJLAVFMTFUYGP-UHFFFAOYSA-N Cc1cc(CCCCCN2CCN(C)CC2)n[o]1 Chemical compound Cc1cc(CCCCCN2CCN(C)CC2)n[o]1 NKJLAVFMTFUYGP-UHFFFAOYSA-N 0.000 description 1
- PXRKWVGPKRKKFP-UHFFFAOYSA-N Cc1cc(CCCOCCN2CCN(C)CC2)n[o]1 Chemical compound Cc1cc(CCCOCCN2CCN(C)CC2)n[o]1 PXRKWVGPKRKKFP-UHFFFAOYSA-N 0.000 description 1
- CCGOLKRCFVKMCO-UHFFFAOYSA-N Cc1cc(CCOCCN2CCN(C)CC2)n[o]1 Chemical compound Cc1cc(CCOCCN2CCN(C)CC2)n[o]1 CCGOLKRCFVKMCO-UHFFFAOYSA-N 0.000 description 1
- BOECVYQYFLWQNP-UHFFFAOYSA-N Cc1cc(COCCCN2CCN(C)CC2)n[o]1 Chemical compound Cc1cc(COCCCN2CCN(C)CC2)n[o]1 BOECVYQYFLWQNP-UHFFFAOYSA-N 0.000 description 1
- OFOLFJNDUSEUPT-UHFFFAOYSA-N Cc1cc(COCCN2CCN(C)CC2)n[o]1 Chemical compound Cc1cc(COCCN2CCN(C)CC2)n[o]1 OFOLFJNDUSEUPT-UHFFFAOYSA-N 0.000 description 1
- LTCXOHTXCPOVIV-UMSPYCQHSA-N Cc1cc(O[C@H](C2)C[C@@H]2NC)ccc1 Chemical compound Cc1cc(O[C@H](C2)C[C@@H]2NC)ccc1 LTCXOHTXCPOVIV-UMSPYCQHSA-N 0.000 description 1
- QEBVSEQGCUZGCV-SECBINFHSA-N Nc1cc(c(C(c(c(F)ccc2NS(N(CC3)C[C@@H]3F)(=O)=O)c2F)=O)c[nH]2)c2nc1 Chemical compound Nc1cc(c(C(c(c(F)ccc2NS(N(CC3)C[C@@H]3F)(=O)=O)c2F)=O)c[nH]2)c2nc1 QEBVSEQGCUZGCV-SECBINFHSA-N 0.000 description 1
- UQPSXJLSPRHBBA-OQWWRJADSA-N O/N=C(\CC1)/c(cc2)c1cc2-c1c[n](-c(cc2)ccc2N2CCN(CCCOc3cccc(C(N4C(CCC(N5)=O)C5=O)=O)c3C4=O)CC2)nc1-c1ccncc1 Chemical compound O/N=C(\CC1)/c(cc2)c1cc2-c1c[n](-c(cc2)ccc2N2CCN(CCCOc3cccc(C(N4C(CCC(N5)=O)C5=O)=O)c3C4=O)CC2)nc1-c1ccncc1 UQPSXJLSPRHBBA-OQWWRJADSA-N 0.000 description 1
- CFJMFGGNHCSIHD-VRPJDWIJSA-N O/N=C(\CC1)/c(cc2)c1cc2-c1c[n](-c(cc2)ccc2N2CCN(CCOCCOc(cc3)cc(C(N4C(CCC(N5)=O)C5=O)=O)c3C4=O)CC2)nc1-c1ccncc1 Chemical compound O/N=C(\CC1)/c(cc2)c1cc2-c1c[n](-c(cc2)ccc2N2CCN(CCOCCOc(cc3)cc(C(N4C(CCC(N5)=O)C5=O)=O)c3C4=O)CC2)nc1-c1ccncc1 CFJMFGGNHCSIHD-VRPJDWIJSA-N 0.000 description 1
- RQPANKYMENZMFC-PHVLXYFRSA-N O/N=C(\CC1)/c(cc2)c1cc2-c1c[n](-c(cc2)ccc2OCCCOc2cc(-c(cccc3C(N4C(CCC(N5)=O)C5=O)=O)c3C4=O)ccc2)nc1-c1ccncc1 Chemical compound O/N=C(\CC1)/c(cc2)c1cc2-c1c[n](-c(cc2)ccc2OCCCOc2cc(-c(cccc3C(N4C(CCC(N5)=O)C5=O)=O)c3C4=O)ccc2)nc1-c1ccncc1 RQPANKYMENZMFC-PHVLXYFRSA-N 0.000 description 1
- KGZUGSKPAMJRRC-UHFFFAOYSA-N O=C(CC1)c(cc2)c1cc2-c1c[n](-c(cc2)ccc2OCc(cccc2)c2OCCOCCCOc(cccc2C(N3C(CCC(N4)=O)C4=O)=O)c2C3=O)nc1-c1ccncc1 Chemical compound O=C(CC1)c(cc2)c1cc2-c1c[n](-c(cc2)ccc2OCc(cccc2)c2OCCOCCCOc(cccc2C(N3C(CCC(N4)=O)C4=O)=O)c2C3=O)nc1-c1ccncc1 KGZUGSKPAMJRRC-UHFFFAOYSA-N 0.000 description 1
- DXQDVHBZWPXJPA-UHFFFAOYSA-N O=C(c(cc1)c2cc1N(C1)CC1N(C1)CC1Oc(cc1)ccc1-[n]1nc(C3C=CN=CC3)c(Br)c1)N(C(CCC(N1)=O)C1=O)C2=O Chemical compound O=C(c(cc1)c2cc1N(C1)CC1N(C1)CC1Oc(cc1)ccc1-[n]1nc(C3C=CN=CC3)c(Br)c1)N(C(CCC(N1)=O)C1=O)C2=O DXQDVHBZWPXJPA-UHFFFAOYSA-N 0.000 description 1
- CCERGJGFOODHOI-NDEPHWFRSA-N O=C(c1c2c(OCCCCN(CC3)CCN3c(cc3)ccc3-[n](cc3Br)nc3-c3ccncc3)ccc1)N([C@@H](CCC(N1)=O)C1=O)C2=O Chemical compound O=C(c1c2c(OCCCCN(CC3)CCN3c(cc3)ccc3-[n](cc3Br)nc3-c3ccncc3)ccc1)N([C@@H](CCC(N1)=O)C1=O)C2=O CCERGJGFOODHOI-NDEPHWFRSA-N 0.000 description 1
- UTSZNJIEZABRKU-OAQYLSRUSA-N O=CCN(CC1)CCN1c(cc1)ccc1-c1cc(c(C(c(c(F)c(cc2)NS(N(CC3)C[C@@H]3F)(=O)=O)c2F)=O)c[nH]2)c2nc1 Chemical compound O=CCN(CC1)CCN1c(cc1)ccc1-c1cc(c(C(c(c(F)c(cc2)NS(N(CC3)C[C@@H]3F)(=O)=O)c2F)=O)c[nH]2)c2nc1 UTSZNJIEZABRKU-OAQYLSRUSA-N 0.000 description 1
- RFWLATFOOGPHAS-AREMUKBSSA-N OC(CN1CCC(CN(CC2)CCN2c(cc2)ccc2-c2cc(c(C(c(c(F)c(cc3)NS(N(CC4)C[C@@H]4F)(=O)=O)c3F)=O)c[nH]3)c3nc2)CC1)=O Chemical compound OC(CN1CCC(CN(CC2)CCN2c(cc2)ccc2-c2cc(c(C(c(c(F)c(cc3)NS(N(CC4)C[C@@H]4F)(=O)=O)c3F)=O)c[nH]3)c3nc2)CC1)=O RFWLATFOOGPHAS-AREMUKBSSA-N 0.000 description 1
- SJCTVMPUXINNPA-UHFFFAOYSA-N OC(c(cc1)c2cc1N(CC1)CCC1N(CC1)CCC1[n](cc1-c(cc3)cc(CC4)c3C4=O)nc1-c1ccncc1)N(C(CCC(N1)=O)C1=O)C2=O Chemical compound OC(c(cc1)c2cc1N(CC1)CCC1N(CC1)CCC1[n](cc1-c(cc3)cc(CC4)c3C4=O)nc1-c1ccncc1)N(C(CCC(N1)=O)C1=O)C2=O SJCTVMPUXINNPA-UHFFFAOYSA-N 0.000 description 1
- YEFDWSQVRHOJFI-UHFFFAOYSA-N OCCCOc(cc1)ccc1-[n](cc1-c(cc2)cc(CC3)c2C3=O)nc1-c1csncc1 Chemical compound OCCCOc(cc1)ccc1-[n](cc1-c(cc2)cc(CC3)c2C3=O)nc1-c1csncc1 YEFDWSQVRHOJFI-UHFFFAOYSA-N 0.000 description 1
- PKXOFPCXFBCGEA-MECOZAJYSA-N OCCOc1cccc2c1C1OC1N([C@@H](CCC(N1)=O)C1=O)C2=O Chemical compound OCCOc1cccc2c1C1OC1N([C@@H](CCC(N1)=O)C1=O)C2=O PKXOFPCXFBCGEA-MECOZAJYSA-N 0.000 description 1
- UHOVQNZJYSORNB-UHFFFAOYSA-N c1ccccc1 Chemical compound c1ccccc1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 1
Images
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2023015526A JP2023065395A (ja) | 2016-12-23 | 2023-02-03 | Ｒａｆ（急速進行性線維肉腫）ポリペプチドの標的分解のための化合物および方法 |
| JP2024180795A JP2025016525A (ja) | 2016-12-23 | 2024-10-16 | Ｒａｆ（急速進行性線維肉腫）ポリペプチドの標的分解のための化合物および方法 |
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662438803P | 2016-12-23 | 2016-12-23 | |
| US62/438,803 | 2016-12-23 | ||
| US201762582698P | 2017-11-07 | 2017-11-07 | |
| US62/582,698 | 2017-11-07 | ||
| PCT/US2017/068322 WO2018119448A1 (en) | 2016-12-23 | 2017-12-22 | Compounds and methods for the targeted degradation of rapidly accelerated fibrosarcoma polypeptides |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023015526A Division JP2023065395A (ja) | 2016-12-23 | 2023-02-03 | Ｒａｆ（急速進行性線維肉腫）ポリペプチドの標的分解のための化合物および方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2020504741A JP2020504741A (ja) | 2020-02-13 |
| JP2020504741A5 true JP2020504741A5 (enExample) | 2021-02-04 |
| JP7679173B2 JP7679173B2 (ja) | 2025-05-19 |
Family
ID=62625473
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019534245A Active JP7679173B2 (ja) | 2016-12-23 | 2017-12-22 | Ｒａｆ（急速進行性線維肉腫）ポリペプチドの標的分解のための化合物および方法 |
| JP2023015526A Pending JP2023065395A (ja) | 2016-12-23 | 2023-02-03 | Ｒａｆ（急速進行性線維肉腫）ポリペプチドの標的分解のための化合物および方法 |
| JP2024180795A Pending JP2025016525A (ja) | 2016-12-23 | 2024-10-16 | Ｒａｆ（急速進行性線維肉腫）ポリペプチドの標的分解のための化合物および方法 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023015526A Pending JP2023065395A (ja) | 2016-12-23 | 2023-02-03 | Ｒａｆ（急速進行性線維肉腫）ポリペプチドの標的分解のための化合物および方法 |
| JP2024180795A Pending JP2025016525A (ja) | 2016-12-23 | 2024-10-16 | Ｒａｆ（急速進行性線維肉腫）ポリペプチドの標的分解のための化合物および方法 |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US10723717B2 (enExample) |
| EP (1) | EP3558994A4 (enExample) |
| JP (3) | JP7679173B2 (enExample) |
| KR (3) | KR20250117470A (enExample) |
| CN (2) | CN117510491A (enExample) |
| AU (2) | AU2017382436C1 (enExample) |
| BR (1) | BR112019012878A2 (enExample) |
| CA (1) | CA3047784A1 (enExample) |
| CO (1) | CO2019007894A2 (enExample) |
| IL (4) | IL325835A (enExample) |
| MX (2) | MX2019007649A (enExample) |
| WO (1) | WO2018119448A1 (enExample) |
Families Citing this family (162)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP5422782B1 (ja) | 2012-12-21 | 2014-02-19 | 独立行政法人放射線医学総合研究所 | 脳内に蓄積したタウタンパク質をイメージングするための新規化合物 |
| US10039809B2 (en) | 2013-12-18 | 2018-08-07 | The California Institute For Biomedical Research | Modified therapeutic agents, stapled peptide lipid conjugates, and compositions thereof |
| US20180228907A1 (en) | 2014-04-14 | 2018-08-16 | Arvinas, Inc. | Cereblon ligands and bifunctional compounds comprising the same |
| JP6817962B2 (ja) | 2015-01-20 | 2021-01-20 | アルビナス・オペレーションズ・インコーポレイテッドＡｒｖｉｎａｓ Ｏｐｅｒａｔｉｏｎｓ， Ｉｎｃ． | ターゲティングされたアンドロゲン受容体分解のための化合物および方法 |
| US12312316B2 (en) | 2015-01-20 | 2025-05-27 | Arvinas Operations, Inc. | Compounds and methods for the targeted degradation of androgen receptor |
| WO2016197114A1 (en) | 2015-06-05 | 2016-12-08 | Arvinas, Inc. | Tank-binding kinase-1 protacs and associated methods of use |
| EP3319944A4 (en) | 2015-07-10 | 2019-04-24 | Arvinas, Inc. | MDM2-BASED MODULATORS OF PROTEOLYSIS AND RELATED USE METHODS |
| EP3337476A4 (en) | 2015-08-19 | 2019-09-04 | Arvinas, Inc. | Compounds and methods for the targeted degradation of bromodomain-containing proteins |
| US20170281784A1 (en) | 2016-04-05 | 2017-10-05 | Arvinas, Inc. | Protein-protein interaction inducing technology |
| CN109562107A (zh) | 2016-05-10 | 2019-04-02 | C4医药公司 | 用于靶蛋白降解的杂环降解决定子体 |
| WO2017197046A1 (en) | 2016-05-10 | 2017-11-16 | C4 Therapeutics, Inc. | C3-carbon linked glutarimide degronimers for target protein degradation |
| CN121974842A (zh) | 2016-05-10 | 2026-05-05 | C4医药公司 | 用于靶蛋白降解的胺连接的c3-戊二酰亚胺降解决定子体 |
| CN109562113A (zh) | 2016-05-10 | 2019-04-02 | C4医药公司 | 用于靶蛋白降解的螺环降解决定子体 |
| EP3512842B1 (en) | 2016-09-15 | 2024-01-17 | Arvinas, Inc. | Indole derivatives as estrogen receptor degraders |
| MX2019005007A (es) | 2016-11-01 | 2019-07-18 | Arvinas Inc | Protac dirigidos a la proteína tau y métodos asociados de uso. |
| IL266842B (en) | 2016-12-01 | 2022-09-01 | Arvinas Operations Inc | History of tetrahydronaphthalene and tetrahydroisoquinoline as estrogen receptor antagonists |
| US11173211B2 (en) | 2016-12-23 | 2021-11-16 | Arvinas Operations, Inc. | Compounds and methods for the targeted degradation of rapidly accelerated Fibrosarcoma polypeptides |
| US10806737B2 (en) | 2016-12-23 | 2020-10-20 | Arvinas Operations, Inc. | Compounds and methods for the targeted degradation of fetal liver kinase polypeptides |
| CN110753693A (zh) | 2016-12-23 | 2020-02-04 | 阿尔维纳斯运营股份有限公司 | Egfr蛋白水解靶向嵌合分子和相关使用方法 |
| IL325835A (en) * | 2016-12-23 | 2026-03-01 | Univ Yale | Compounds and methods for the targeted degradation of rapidly accelerated fibrosarcoma polypeptides |
| US11191741B2 (en) | 2016-12-24 | 2021-12-07 | Arvinas Operations, Inc. | Compounds and methods for the targeted degradation of enhancer of zeste homolog 2 polypeptide |
| US11040027B2 (en) | 2017-01-17 | 2021-06-22 | Heparegenix Gmbh | Protein kinase inhibitors for promoting liver regeneration or reducing or preventing hepatocyte death |
| IL300417A (en) | 2017-01-26 | 2023-04-01 | Arvinas Operations Inc | Bifunctional benzothiophene compounds, preparations containing them and their use in therapy |
| IL319363A (en) | 2017-01-31 | 2025-05-01 | Arvinas Operations Inc | Cervalon ligands and bifunctional compounds containing them |
| WO2018200981A1 (en) * | 2017-04-28 | 2018-11-01 | Quartz Therapeutics, Inc. | Raf-degrading conjugate compounds |
| EP4717317A3 (en) | 2017-06-20 | 2026-06-03 | C4 Therapeutics, Inc. | N/o-linked degrons and degronimers for protein degradation |
| TWI793151B (zh) | 2017-08-23 | 2023-02-21 | 瑞士商諾華公司 | 3-(1-氧異吲哚啉-2-基)之氫吡啶-2,6-二酮衍生物及其用途 |
| WO2019043217A1 (en) | 2017-09-04 | 2019-03-07 | F. Hoffmann-La Roche Ag | DIHYDROBENZIMIDAZOLONES |
| CN118108706A (zh) | 2017-09-04 | 2024-05-31 | C4医药公司 | 戊二酰亚胺 |
| WO2019043208A1 (en) | 2017-09-04 | 2019-03-07 | F. Hoffmann-La Roche Ag | DIHYDROQUINOLINONES |
| US10632209B2 (en) | 2017-11-10 | 2020-04-28 | The Regents Of The University Of Michigan | ASH1L inhibitors and methods of treatment therewith |
| EP3710002A4 (en) | 2017-11-16 | 2021-07-07 | C4 Therapeutics, Inc. | DEGRADER AND DEGRONE FOR TARGETED PROTEIN DEGRADATION |
| US11065231B2 (en) | 2017-11-17 | 2021-07-20 | Arvinas Operations, Inc. | Compounds and methods for the targeted degradation of interleukin-1 receptor- associated kinase 4 polypeptides |
| JP2021512153A (ja) | 2018-01-26 | 2021-05-13 | イエール ユニバーシティ | タンパク質分解のイミド系モジュレーターおよび使用方法 |
| CN111902141A (zh) | 2018-03-26 | 2020-11-06 | C4医药公司 | 用于ikaros降解的羟脑苷脂结合剂 |
| US12539292B2 (en) | 2018-04-01 | 2026-02-03 | Arvinas Operations, Inc. | BRM targeting compounds and associated methods of use |
| BR112020020307A2 (pt) | 2018-04-04 | 2021-01-12 | Arvinas Operations, Inc. | Moduladores de proteólise e métodos de uso associados |
| EP3778590A4 (en) | 2018-04-09 | 2021-12-22 | ShanghaiTech University | ANTI PROTEIN DEGRADATION COMPOUND, ANTITUMOR APPLICATION, INTERMEDIATE THEREOF, AND INTERMEDIATE USE |
| CA3095912A1 (en) * | 2018-04-13 | 2019-10-17 | Arvinas Operations, Inc. | Cereblon ligands and bifunctional compounds comprising the same |
| WO2019204354A1 (en) | 2018-04-16 | 2019-10-24 | C4 Therapeutics, Inc. | Spirocyclic compounds |
| CN112384517B (zh) | 2018-05-09 | 2023-07-14 | 新旭生技股份有限公司 | 杂芳基化合物及其用途 |
| BR112020023136A2 (pt) | 2018-05-14 | 2021-02-09 | Nuvation Bio Inc. | compostos de alvo de receptor de hormônio nuclear anticâncer |
| EP3578561A1 (en) | 2018-06-04 | 2019-12-11 | F. Hoffmann-La Roche AG | Spiro compounds |
| AR116109A1 (es) * | 2018-07-10 | 2021-03-31 | Novartis Ag | Derivados de 3-(5-amino-1-oxoisoindolin-2-il)piperidina-2,6-diona y usos de los mismos |
| BR122022012697B1 (pt) | 2018-07-10 | 2023-04-04 | Novartis Ag | Usos de derivados de 3-(5-hidróxi-1-oxoisoindolin-2-il)piperidina-2,6- diona, e kit |
| WO2020027225A1 (ja) | 2018-07-31 | 2020-02-06 | ファイメクス株式会社 | 複素環化合物 |
| US11707452B2 (en) | 2018-08-20 | 2023-07-25 | Arvinas Operations, Inc. | Modulators of alpha-synuclein proteolysis and associated methods of use |
| MX2021001957A (es) | 2018-08-22 | 2021-07-15 | Cullgen Shanghai Inc | Compuestos de degradacion y metodos de uso del receptor de tropomiosina quinasa (trk). |
| US11969472B2 (en) | 2018-08-22 | 2024-04-30 | Cullgen (Shanghai), Inc. | Tropomyosin receptor kinase (TRK) degradation compounds and methods of use |
| CN119219628A (zh) * | 2018-09-07 | 2024-12-31 | 阿尔维纳斯运营股份有限公司 | 用于迅速加速性纤维肉瘤多肽的靶向降解的多环化合物和方法 |
| CA3121667A1 (en) * | 2018-09-30 | 2020-04-02 | Shanghai Institute Of Materia Medica, Chinese Academy Of Sciences | Isoindoline compound, preparation method, pharmaceutical composition and use thereof |
| EP3864030A4 (en) * | 2018-10-12 | 2022-09-21 | The Scripps Research Institute | Compounds and methods for dcaf-mediated protein degradation |
| WO2020118098A1 (en) * | 2018-12-05 | 2020-06-11 | Vividion Therapeutics, Inc. | Substituted isoindolinones as modulators of cereblon-mediated neo-substrate recruitment |
| AU2019392231B2 (en) * | 2018-12-06 | 2022-10-20 | Shanghai Institute Of Materia Medica, Chinese Academy Of Sciences | Isoindoline compound, and preparation method, pharmaceutical composition, and application of isoindoline compound |
| EP3897631A4 (en) | 2018-12-20 | 2022-11-23 | C4 Therapeutics, Inc. | TARGETED PROTEIN BREAKDOWN |
| KR102876423B1 (ko) * | 2019-02-07 | 2025-10-24 | 한국화학연구원 | 표적 단백질 ｅｅｄ 분해 유도 데그라듀서, 이의 제조방법 및 이를 유효성분으로 함유하는 ｅｅｄ, ｅｚｈ2, 또는 ｐｒｃ2 관련 질환의 예방 또는 치료용 약학적 조성물 |
| EP3932922A4 (en) | 2019-02-25 | 2022-05-11 | ShanghaiTech University | SULPHUR-CONTAINING COMPOUND BASED ON A GLUTARIMIDE FRAMEWORK AND ITS USE |
| WO2020176424A1 (en) * | 2019-02-25 | 2020-09-03 | Chdi Foundation, Inc. | Compounds for targeting mutant huntingtin protein and uses thereof |
| US12186401B2 (en) | 2019-03-01 | 2025-01-07 | Ontario Institute for Cancer Research (OICR) and Sinai Health System | Amide-based proteolysis modulators of B-rapidly accelerated fibrosarcoma (BRAF) and associated uses |
| ES2995214T3 (en) | 2019-03-06 | 2025-02-07 | C4 Therapeutics Inc | Heterocyclic compounds for medical treatment |
| KR102947433B1 (ko) | 2019-04-12 | 2026-04-06 | 씨4 테라퓨틱스, 인코포레이티드 | 이카로스 및 아이올로스의 트리시클릭 분해제 |
| WO2020214555A1 (en) | 2019-04-16 | 2020-10-22 | Northwestern University | Bifunctional compounds comprising apcin-a and their use in the treatment of cancer |
| CN113811333B (zh) | 2019-05-14 | 2024-03-12 | 诺维逊生物股份有限公司 | 靶向抗癌核激素受体的化合物 |
| CN118027041A (zh) * | 2019-05-31 | 2024-05-14 | 西藏海思科制药有限公司 | 一种btk抑制剂环衍生物及其制备方法和药学上的应用 |
| CN114245807B (zh) | 2019-06-25 | 2025-05-02 | 吉利德科学公司 | Flt3l-fc融合蛋白和使用方法 |
| EP3999182A1 (en) | 2019-07-17 | 2022-05-25 | Arvinas Operations, Inc. | Tau-protein targeting compounds and associated methods of use |
| WO2021016521A1 (en) * | 2019-07-25 | 2021-01-28 | Beth Israel Deaconess Medical Center, Inc. | Photo induced control of protein destruction |
| JP2021024787A (ja) | 2019-07-31 | 2021-02-22 | ファイメクス株式会社 | 複素環化合物 |
| JP7764027B2 (ja) | 2019-07-31 | 2025-11-05 | ファイメクス株式会社 | 複素環化合物 |
| WO2021023233A1 (zh) | 2019-08-05 | 2021-02-11 | 上海科技大学 | Egfr蛋白降解剂及其抗肿瘤应用 |
| WO2021041348A1 (en) | 2019-08-26 | 2021-03-04 | Arvinas Operations, Inc. | Methods of treating breast cancer with tetrahydronaphthalene derivatives as estrogen receptor degraders |
| WO2021061644A1 (en) * | 2019-09-23 | 2021-04-01 | Accutar Biotechnology Inc. | Novel substituted quinoline-8-carbonitrile derivatives with androgen receptor degradation activity and uses thereof |
| EP4034114A4 (en) | 2019-09-23 | 2023-07-26 | Accutar Biotechnology Inc. | Novel ureas having androgen receptor degradation activity and uses thereof |
| EP3795570B1 (en) * | 2019-09-23 | 2022-02-23 | Accutar Biotechnology Inc. | Substituted quinoline-8-carbonitrile derivatives having androgen receptor degradation activity and uses thereof |
| MX2022004526A (es) | 2019-10-17 | 2022-07-21 | Arvinas Operations Inc | Moléculas bifuncionales que contienen una porción de unión a la ligasa de ubiquitina e3 unida a una porción de direccionamiento a bcl6. |
| EP4058464A1 (en) | 2019-11-13 | 2022-09-21 | Nuvation Bio Inc. | Anti-cancer nuclear hormone receptor-targeting compounds |
| CA3161455A1 (en) * | 2019-11-13 | 2021-05-20 | Aprinoia Therapeutics Limited | Compounds for degrading tau protein aggregates and uses thereof |
| JP7629459B2 (ja) | 2019-11-19 | 2025-02-13 | ブリストル－マイヤーズ スクイブ カンパニー | Ｈｅｌｉｏｓタンパク質の阻害剤として有用な化合物 |
| EP4069726A4 (en) | 2019-12-04 | 2024-03-20 | The Scripps Research Institute | GLP2 RECEPTOR AGONISTS AND METHOD OF USE |
| CN110950877B (zh) * | 2019-12-11 | 2022-06-28 | 齐鲁工业大学 | 一种双检测荧光探针、制备方法及其在检测硫化氢和铜离子中的应用 |
| JP7871189B2 (ja) * | 2019-12-17 | 2026-06-08 | オリオニス バイオサイエンシズ，インコーポレイテッド | タンパク質の動員および／または分解を調節する化合物 |
| US20230099031A1 (en) * | 2019-12-17 | 2023-03-30 | Orionis Biosciences, Inc. | Bifunctional agents for protein recruitment and/or degradation |
| PH12022551482A1 (en) | 2019-12-18 | 2023-11-29 | Novartis Ag | 3-(5-methoxy-1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof |
| WO2021127443A1 (en) | 2019-12-19 | 2021-06-24 | Arvinas Operations, Inc. | Compounds and methods for the targeted degradation of androgen receptor |
| EP4681715A3 (en) | 2019-12-20 | 2026-01-28 | C4 Therapeutics, Inc. | Isoindolinone and indazole compounds for the degradation of egfr |
| TWI890283B (zh) | 2020-02-14 | 2025-07-11 | 美商基利科學股份有限公司 | 結合ccr8之抗體及融合蛋白及其用途 |
| BR112022016901A2 (pt) | 2020-02-26 | 2022-12-06 | Cullgen Shanghai Inc | Compostos de degradação do receptor de tropomiosina quinase (trk) e métodos de uso |
| CN119823124A (zh) | 2020-03-05 | 2025-04-15 | C4医药公司 | 用于brd9的靶向降解的化合物 |
| TW202140441A (zh) | 2020-03-23 | 2021-11-01 | 美商必治妥美雅史谷比公司 | 經取代之側氧基異吲哚啉化合物 |
| US20220370416A1 (en) * | 2020-04-06 | 2022-11-24 | Arvinas Operations, Inc. | Compounds and methods for targeted degradation of kras |
| PT4161935T (pt) | 2020-06-09 | 2025-08-14 | Prelude Therapeutics Inc | Compostos direcionados a brm e métodos de utilização associados |
| AU2021293907A1 (en) * | 2020-06-17 | 2023-01-19 | Dana-Farber Cancer Institute, Inc. | Targeted aberrant alpha-synuclein species and induced ubiquitination and proteosomal clearance via co-recruitment of an E3-ligase system |
| WO2021255212A1 (en) | 2020-06-19 | 2021-12-23 | F. Hoffmann-La Roche Ag | Braf degraders |
| WO2021255213A1 (en) * | 2020-06-19 | 2021-12-23 | F. Hoffmann-La Roche Ag | Heterobifunctional compounds as degraders of braf |
| KR102559329B1 (ko) * | 2020-07-02 | 2023-07-25 | 포항공과대학교 산학협력단 | 신규한 프로탁 키메라 화합물, 이를 포함하는 표적 단백질 분해를 통한 질환의 예방, 개선 또는 치료용 약학적 조성물 |
| WO2022019597A1 (ko) * | 2020-07-21 | 2022-01-27 | 주식회사 유빅스테라퓨틱스 | 안드로겐 수용체 분해용 화합물 및 이들의 의약 용도 |
| CN117964623A (zh) * | 2020-08-05 | 2024-05-03 | 上海领泰生物医药科技有限公司 | 靶向蛋白降解化合物及其制备方法和应用 |
| CN116490186B (zh) | 2020-08-05 | 2025-10-31 | C4医药公司 | 用于ret的靶向降解的化合物 |
| CA3186926A1 (en) * | 2020-08-07 | 2022-02-10 | Francis Barany | Therapeutically useful cure-pro molecules for e3 ligase mediated degradation of proteins, and methods of making and using them |
| EP4192824A4 (en) * | 2020-08-07 | 2024-08-28 | Cornell University | THERAPEUTIC COMPOSITION OF CURE-PRO COMPOUNDS FOR TARGETED DEGRADATION OF BET DOMAIN PROTEINS AND METHODS OF MAKING AND USING SAME |
| CN117062814A (zh) * | 2020-08-28 | 2023-11-14 | 阿维纳斯运营公司 | 快速加速纤维肉瘤蛋白降解的化合物和相关使用方法 |
| WO2022047145A1 (en) | 2020-08-28 | 2022-03-03 | Arvinas Operations, Inc. | Rapidly accelerating fibrosarcoma protein degrading compounds and associated methods of use |
| AU2021342287A1 (en) | 2020-09-14 | 2023-04-13 | Arvinas Operations, Inc. | Crystalline forms of a compound for the targeted degradation of estrogen receptor |
| WO2022066835A1 (en) | 2020-09-23 | 2022-03-31 | St. Jude Children's Research Hospital, Inc. | Substituted n-(2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-5-yl)arylsulfonamide analogs as modulators of cereblon protein |
| CN117242060B (zh) | 2021-01-13 | 2026-07-17 | 蒙特罗莎治疗股份有限公司 | 异吲哚啉酮化合物 |
| KR102532692B1 (ko) * | 2021-03-15 | 2023-05-16 | (주)피알지에스앤텍 | 신경섬유종증 2형 증후군 예방 또는 치료용 조성물 |
| EP4313991A1 (en) | 2021-03-23 | 2024-02-07 | Nuvation Bio Inc. | Anti-cancer nuclear hormone receptor-targeting compounds |
| PE20231941A1 (es) | 2021-04-06 | 2023-12-05 | Bristol Myers Squibb Co | Compuestos de oxoisoindolina sustituidos con piridinilo |
| CN118388454A (zh) | 2021-04-16 | 2024-07-26 | 阿尔维纳斯运营股份有限公司 | Bcl6蛋白水解的调节剂和其相关使用方法 |
| WO2022235585A1 (en) | 2021-05-03 | 2022-11-10 | Nuvation Bio Inc. | Anti-cancer nuclear hormone receptor-targeting compounds |
| US20240287076A1 (en) | 2021-05-05 | 2024-08-29 | Biogen Ma Inc. | Compounds for targeting degradation of bruton's tyrosine kinase |
| WO2022245671A1 (en) | 2021-05-18 | 2022-11-24 | Gilead Sciences, Inc. | Methods of using flt3l-fc fusion proteins |
| WO2022255888A1 (en) * | 2021-06-01 | 2022-12-08 | Captor Therapeutics S.A. | Targeted protein degradation using bifunctional compounds that bind ubiquitin ligase and target mcl-1 protein |
| WO2022254362A1 (en) | 2021-06-03 | 2022-12-08 | Novartis Ag | 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives and medical uses thereof |
| WO2022261627A1 (en) * | 2021-06-07 | 2022-12-15 | The General Hospital Corporation | Inhibitors of ttbk1 |
| AU2022290851A1 (en) | 2021-06-08 | 2023-11-23 | C4 Therapeutics, Inc. | Therapeutics for the degradation of mutant braf |
| AU2022289610A1 (en) | 2021-06-09 | 2024-01-25 | The Scripps Research Institute | Long-acting dual gip/glp-1 peptide conjugates and methods of use |
| WO2023283372A1 (en) | 2021-07-07 | 2023-01-12 | Biogen Ma Inc. | Compounds for targeting degradation of irak4 proteins |
| CA3224732A1 (en) | 2021-07-07 | 2023-01-12 | Kevin M. Guckian | Compounds for targeting degradation of irak4 proteins |
| WO2023023941A1 (en) * | 2021-08-24 | 2023-03-02 | Biofront Ltd (Cayman) | Hpk1 degraders, compositions comprising the hpki degrader, and methods of using the same |
| EP4395549A1 (en) | 2021-09-01 | 2024-07-10 | Oerth Bio LLC | Compositions and methods for targeted degradation of proteins in a plant cell |
| CN115785199A (zh) * | 2021-09-10 | 2023-03-14 | 润佳（苏州）医药科技有限公司 | 一种双官能化合物及其用途 |
| JP2024539269A (ja) * | 2021-10-22 | 2024-10-28 | グルータクス セラピューティクス （シャンハイ） カンパニー、リミテッド | Ｃｒｂｎ ｅ３リガーゼリガンド化合物、当該リガンド化合物に基づいて開発したタンパク質分解剤及びそれらの応用 |
| EP4423078A1 (en) | 2021-10-28 | 2024-09-04 | Gilead Sciences, Inc. | Pyridizin-3(2h)-one derivatives |
| PE20241186A1 (es) | 2021-10-29 | 2024-06-03 | Gilead Sciences Inc | Compuestos de cd73 |
| CN115894450B (zh) * | 2021-11-30 | 2023-09-12 | 山东如至生物医药科技有限公司 | 一种新型多环类化合物及其组合物和用途 |
| US20240124412A1 (en) | 2021-12-22 | 2024-04-18 | Gilead Sciences, Inc. | Ikaros zinc finger family degraders and uses thereof |
| CN118488948A (zh) | 2021-12-22 | 2024-08-13 | 吉利德科学公司 | Ikaros锌指家族降解剂及其用途 |
| CA3248911A1 (en) | 2022-01-28 | 2023-08-03 | Gilead Sciences, Inc. | POLY(ADENOSINE DIPHOSPHATE-RIBOSE) POLYMERASE 7 INHIBITORS |
| WO2023143494A1 (zh) * | 2022-01-28 | 2023-08-03 | 甘李药业股份有限公司 | 新型protac化合物 |
| PL4245756T3 (pl) | 2022-03-17 | 2025-02-17 | Gilead Sciences, Inc. | Środki degradujące palec cynkowy z rodziny ikaros i ich zastosowania |
| US12662467B2 (en) | 2022-04-18 | 2026-06-23 | BioThery X, Inc. | Isoindolinones, pharmaceutical compositions, and therapeutic applications |
| EP4511128A1 (en) | 2022-04-20 | 2025-02-26 | Kumquat Biosciences Inc. | Macrocyclic heterocycles and uses thereof |
| EP4511127A1 (en) | 2022-04-21 | 2025-02-26 | Gilead Sciences, Inc. | Kras g12d modulating compounds |
| IL316803A (en) | 2022-06-06 | 2025-01-01 | C4 Therapeutics Inc | Bicyclic glutarimide-modified cervalon-binding agents |
| WO2024006929A1 (en) | 2022-07-01 | 2024-01-04 | Gilead Sciences, Inc. | Cd73 compounds |
| WO2024050016A1 (en) | 2022-08-31 | 2024-03-07 | Oerth Bio Llc | Compositions and methods for targeted inhibition and degradation of proteins in an insect cell |
| EP4584258A1 (en) | 2022-09-07 | 2025-07-16 | Arvinas Operations, Inc. | Rapidly accelerated fibrosarcoma (raf) degrading compounds and associated methods of use |
| EP4638436A1 (en) | 2022-12-22 | 2025-10-29 | Gilead Sciences, Inc. | Prmt5 inhibitors and uses thereof |
| EP4644382A4 (en) * | 2022-12-27 | 2026-04-01 | Gluetacs Therapeutics Shanghai Co Ltd | ISOINDOLINONE SKELETON-BASED COMPOUND WITH SULFUR/OXYGEN SUBSTITUTED GLUTARIMIDE AND ITS USE |
| PE20260006A1 (es) | 2023-01-26 | 2026-01-06 | Arvinas Operations Inc | Protacs degradadores de kras basados en cereblon y usos relacionados con los mismos |
| WO2024215754A1 (en) | 2023-04-11 | 2024-10-17 | Gilead Sciences, Inc. | Kras modulating compounds |
| PE20260121A1 (es) | 2023-04-21 | 2026-01-16 | Gilead Sciences Inc | Inhibidores de prmt5 y usos de los mismos |
| WO2024243441A1 (en) | 2023-05-24 | 2024-11-28 | Kumquat Biosciences Inc. | Heterocyclic compounds and uses thereof |
| EP4735451A1 (en) | 2023-06-30 | 2026-05-06 | Kumquat Biosciences Inc. | Substituted condensed tricyclic amine compounds and uses thereof as ras inhibitors |
| JP2026522894A (ja) | 2023-06-30 | 2026-07-09 | ギリアード サイエンシーズ， インコーポレイテッド | Ｋｒａｓ調節化合物 |
| AU2024297978A1 (en) | 2023-07-26 | 2026-02-05 | Gilead Sciences, Inc. | Parp7 inhibitors |
| CN121568935A (zh) | 2023-07-26 | 2026-02-24 | 吉利德科学公司 | Parp7抑制剂 |
| WO2025049555A1 (en) | 2023-08-31 | 2025-03-06 | Oerth Bio Llc | Compositions and methods for targeted inhibition and degradation of proteins in an insect cell |
| US20250109147A1 (en) | 2023-09-08 | 2025-04-03 | Gilead Sciences, Inc. | Kras g12d modulating compounds |
| EP4774280A1 (en) | 2023-09-08 | 2026-07-15 | Gilead Sciences, Inc. | Kras g12d modulating compounds |
| CN122228262A (zh) | 2023-11-02 | 2026-06-16 | 金橘生物科技公司 | 降解剂及其用途 |
| WO2025096589A1 (en) | 2023-11-03 | 2025-05-08 | Gilead Sciences, Inc. | Prmt5 inhibitors and uses thereof |
| CN122555560A (zh) | 2023-12-21 | 2026-08-11 | 丹娜-法伯癌症研究院 | 激酶抑制和降解 |
| US20250230168A1 (en) | 2023-12-22 | 2025-07-17 | Gilead Sciences, Inc. | Azaspiro wrn inhibitors |
| WO2025235298A1 (en) * | 2024-05-07 | 2025-11-13 | Nikang Therapeutics, Inc. | Bifunctional compounds containing thiazolyl derivatives for degrading certain cyclin-dependent kinase via ubiquitin proteasome pathway |
| WO2025245003A1 (en) | 2024-05-21 | 2025-11-27 | Gilead Sciences, Inc. | Prmt5 inhibitors and uses thereof |
| US20260098049A1 (en) | 2024-08-12 | 2026-04-09 | Gilead Sciences, Inc. | Kras modulating compounds |
| CN121735910A (zh) * | 2024-09-27 | 2026-03-27 | 上海交通大学 | 一种模块化的分子胶化合物库及其构建方法和应用 |
| US20260130893A1 (en) | 2024-10-21 | 2026-05-14 | Gilead Sciences, Inc. | Prmt5 inhibitors and uses thereof |
| WO2026136515A1 (en) | 2024-12-19 | 2026-06-25 | Gilead Sciences, Inc. | Parp7 inhibitors |
| WO2026151924A1 (en) * | 2025-01-09 | 2026-07-16 | Triana Biomedicines, Inc. | 2-(2, 6-dioxopiperidine-3-yl)-1, 3-dioxoisoindoline derivatives bearing an heteroaryl group as anaplastic lymphoma kinase (alk) degraders and uses thereof |
Family Cites Families (125)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4522811A (en) | 1982-07-08 | 1985-06-11 | Syntex (U.S.A.) Inc. | Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides |
| DE69740140D1 (de) | 1996-07-24 | 2011-04-14 | Celgene Corp | Substituierte 2-(2,6-Dioxopiperidin-3-yl)-phthalimide und Oxoisoindoline und Verfahren zur Verringerung der TNF-Alpha-Stufen |
| ATE460423T1 (de) | 1997-05-14 | 2010-03-15 | Sloan Kettering Inst Cancer | Verfahren und zubereitungen zur zerstörung bestimmter proteine |
| GB9716557D0 (en) | 1997-08-06 | 1997-10-08 | Glaxo Group Ltd | Benzylidene-1,3-dihydro-indol-2-one derivatives having anti-cancer activity |
| US6306663B1 (en) | 1999-02-12 | 2001-10-23 | Proteinex, Inc. | Controlling protein levels in eucaryotic organisms |
| EP1176959B1 (en) | 1999-05-05 | 2006-03-08 | Merck & Co., Inc. | Novel prolines as antimicrobial agents |
| AU2001295041A1 (en) | 2000-09-08 | 2002-03-22 | California Institute Of Technology | Proteolysis targeting chimeric pharmaceutical |
| US7208157B2 (en) | 2000-09-08 | 2007-04-24 | California Institute Of Technology | Proteolysis targeting chimeric pharmaceutical |
| US20030045552A1 (en) | 2000-12-27 | 2003-03-06 | Robarge Michael J. | Isoindole-imide compounds, compositions, and uses thereof |
| WO2002066512A1 (en) | 2001-02-16 | 2002-08-29 | E.I. Dupont De Nemours And Company | Angiogenesis-inhibitory tripeptides, compositions and their methods of use |
| HN2002000136A (es) | 2001-06-11 | 2003-07-31 | Basf Ag | Inhibidores de la proteasa del virus hiv, compuestos que contienen a los mismos, sus usos farmaceuticos y los materiales para su sintesis |
| US7030141B2 (en) | 2001-11-29 | 2006-04-18 | Christopher Franklin Bigge | Inhibitors of factor Xa and other serine proteases involved in the coagulation cascade |
| CA2491041A1 (en) | 2002-07-02 | 2004-01-15 | Novartis Ag | Peptide inhibitors of smac protein binding to inhibitor of apoptosis proteins (iap) |
| EP1651595A2 (en) | 2003-05-30 | 2006-05-03 | Rigel Pharmaceuticals, Inc. | Ubiquitin ligase inhibitors |
| BRPI0506883A (pt) | 2004-01-16 | 2007-05-29 | Univ Michigan | miméticos de smac conformacionalmente comprimidos e seus usos |
| US7345081B2 (en) | 2004-03-23 | 2008-03-18 | Genentech, Inc. | Azabicyclo-octane inhibitors of IAP |
| PL2253614T3 (pl) | 2004-04-07 | 2013-03-29 | Novartis Ag | Inhibitory IAP |
| KR100926203B1 (ko) | 2004-07-02 | 2009-11-09 | 제넨테크, 인크. | Ｉａｐ의 억제제 |
| MX2007007195A (es) | 2004-12-20 | 2007-10-08 | Genentech Inc | Inhibidores de pirrolidina de iap. |
| TW200639163A (en) * | 2005-02-04 | 2006-11-16 | Genentech Inc | RAF inhibitor compounds and methods |
| EA012810B1 (ru) | 2005-02-25 | 2009-12-30 | Тетралоджик Фармасеутикалс | Димерные ингибиторы ингибиторов белков апоптоза (iap) |
| CN100383139C (zh) | 2005-04-07 | 2008-04-23 | 天津和美生物技术有限公司 | 可抑制细胞释放肿瘤坏死因子的哌啶-2，6-二酮衍生物 |
| US20060252698A1 (en) | 2005-04-20 | 2006-11-09 | Malcolm Bruce A | Compounds for inhibiting cathepsin activity |
| MY153898A (en) | 2005-06-22 | 2015-04-15 | Plexxikon Inc | Compounds and methods for kinase modulation, and indications therefor |
| CA2822094C (en) | 2005-08-31 | 2015-10-27 | Celgene Corporation | Isoindole-imide compounds and compositions comprising and methods of using the same |
| WO2007106670A2 (en) | 2006-03-03 | 2007-09-20 | Novartis Ag | N-formyl hydroxylamine compounds |
| WO2007101347A1 (en) | 2006-03-07 | 2007-09-13 | Aegera Therapeutics Inc. | Bir domain binding compounds |
| ES2525585T3 (es) | 2006-05-05 | 2014-12-26 | The Regents Of The University Of Michigan | Intermedios para la preparación de miméticos de SMAC bivalentes |
| AU2007275415A1 (en) | 2006-07-20 | 2008-01-24 | Ligand Pharmaceuticals Incorporated | Proline urea CCR1 antagonists for the treatment of autoimmune diseases or inflammation |
| US20100056495A1 (en) | 2006-07-24 | 2010-03-04 | Tetralogic Pharmaceuticals Corporation | Dimeric iap inhibitors |
| AU2007290407A1 (en) | 2006-08-30 | 2008-03-06 | Celgene Corporation | 5-substituted isoindoline compounds |
| RU2448101C2 (ru) | 2006-08-30 | 2012-04-20 | Селджин Корпорейшн | 5-замещенные изоиндолиновые соединения |
| WO2008054827A2 (en) | 2006-11-03 | 2008-05-08 | Pharmacyclics, Inc. | Bruton's tyrosine kinase activity probe and method of using |
| WO2008109057A1 (en) | 2007-03-02 | 2008-09-12 | Dana-Farber Cancer Institute, Inc. | Organic compounds and their uses |
| CA2684169C (en) | 2007-04-12 | 2012-06-19 | Joyant Pharmaceuticals, Inc. | Smac mimetic dimers and trimers useful as anti-cancer agents |
| WO2008128171A2 (en) | 2007-04-13 | 2008-10-23 | The Regents Of The University Of Michigan | Diazo bicyclic smac mimetics and the uses thereof |
| NZ598890A (en) | 2007-04-30 | 2013-10-25 | Genentech Inc | Inhibitors of iap |
| WO2008144925A1 (en) | 2007-05-30 | 2008-12-04 | Aegera Therapeutics Inc. | Iap bir domain binding compounds |
| US8415340B2 (en) | 2007-07-25 | 2013-04-09 | Bristol-Myers Squibb Company | Triazine kinase inhibitors |
| EP2058312A1 (en) | 2007-11-09 | 2009-05-13 | Universita' degli Studi di Milano | SMAC mimetic compounds as apoptosis inducers |
| CA2957226C (en) | 2008-10-29 | 2018-08-14 | Celgene Corporation | Isoindoline compounds for use in the treatment of cancer |
| WO2010107485A1 (en) | 2009-03-17 | 2010-09-23 | The Trustees Of Columbia University In The City Of New York | E3 ligase inhibitors |
| WO2010141805A1 (en) | 2009-06-05 | 2010-12-09 | Janssen Pharmaceutica Nv | Heterocyclic amides as modulators of trpa1 |
| WO2011008260A2 (en) | 2009-07-13 | 2011-01-20 | President And Fellows Of Harvard College | Bifunctional stapled polypeptides and uses thereof |
| EP2493879B1 (en) | 2009-10-28 | 2014-05-14 | Joyant Pharmaceuticals, Inc. | Dimeric smac mimetics |
| SG183257A1 (en) | 2010-02-11 | 2012-09-27 | Celgene Corp | Arylmethoxy isoindoline derivatives and compositions comprising and methods of using the same |
| EP2588129A4 (en) | 2010-06-30 | 2014-07-09 | Univ Brandeis | ON SMALL MOLECULES TARGETED PROTEIN REMOVAL |
| JP5852658B2 (ja) | 2010-09-24 | 2016-02-03 | ザ リージェンツ オブ ザ ユニバーシティー オブ ミシガン | デユビキチナーゼ阻害剤およびその使用方法 |
| EP2649099A4 (en) | 2010-12-07 | 2016-10-19 | Univ Yale | SMALL MOLECULAR HYDROPHOBIC LABELING OF FUSION PROTEINS AND INDUCED REMOVAL FROM THIS |
| WO2012090104A1 (en) | 2010-12-31 | 2012-07-05 | Kareus Therapeutics, Sa | Methods and compositions for designing novel conjugate therapeutics |
| US8889684B2 (en) * | 2011-02-02 | 2014-11-18 | Boehringer Ingelheim International Gmbh | Azaindolylphenyl sulfonamides as serine/threonine kinase inhibitors |
| PE20141360A1 (es) * | 2011-02-07 | 2014-10-13 | Plexxikon Inc | Compuestos y metodos para la modulacion de quinasas e indicaciones para los mismos. |
| WO2012149299A2 (en) | 2011-04-29 | 2012-11-01 | Celgene Corporaiton | Methods for the treatment of cancer and inflammatory diseases using cereblon as a predictor |
| MX352672B (es) | 2011-09-27 | 2017-12-04 | Amgen Inc | Compuestos heterocíclicos como inhibidores de mdm2 para el tratamiento del cáncer. |
| WO2013071039A1 (en) | 2011-11-09 | 2013-05-16 | Ensemble Therapeutics | Macrocyclic compounds for inhibition of inhibitors of apoptosis |
| US20140309265A1 (en) | 2011-11-09 | 2014-10-16 | Ensemble Therapeutics | Macrocyclic compounds for inhibition of inhibitors of apoptosis |
| CN103159736B (zh) * | 2011-12-10 | 2015-05-13 | 通化济达医药有限公司 | 取代的吡唑激酶抑制剂 |
| DK2797888T3 (en) | 2011-12-31 | 2016-09-19 | Beigene Ltd | Fused tricyclic compounds as RAF kinase inhibitors |
| WO2013106646A2 (en) | 2012-01-12 | 2013-07-18 | Yale University | Compounds and methods for the inhibition of vcb e3 ubiquitin ligase |
| KR102438072B1 (ko) * | 2012-01-12 | 2022-08-31 | 예일 유니버시티 | E3 유비퀴틴 리가아제에 의한 표적 단백질 및 다른 폴리펩티드의 증진된 분해를 위한 화합물 및 방법 |
| WO2013169858A1 (en) * | 2012-05-08 | 2013-11-14 | The Broad Institute, Inc. | Diagnostic and treatment methods in patients having or at risk of developing resistance to cancer therapy |
| WO2013170147A1 (en) | 2012-05-11 | 2013-11-14 | Yale University | Compounds useful for promoting protein degradation and methods using same |
| EP2855483B1 (en) | 2012-05-24 | 2017-10-25 | Novartis AG | Pyrrolopyrrolidinone compounds |
| CN107540594A (zh) | 2012-05-30 | 2018-01-05 | 霍夫曼-拉罗奇有限公司 | 取代的吡咯烷‑2‑甲酰胺 |
| US9345740B2 (en) | 2012-07-10 | 2016-05-24 | Bristol-Myers Squibb Company | IAP antagonists |
| WO2014020502A2 (en) | 2012-07-31 | 2014-02-06 | Novartis Ag | Markers associated with human double minute 2 inhibitors |
| EP2882740B1 (en) | 2012-08-09 | 2017-03-01 | Bristol-Myers Squibb Company | Iap antagonists |
| TWI586668B (zh) | 2012-09-06 | 2017-06-11 | 第一三共股份有限公司 | 二螺吡咯啶衍生物之結晶 |
| US9783573B2 (en) | 2012-09-18 | 2017-10-10 | Bristol-Myers Squibb Company | IAP antagonists |
| JP6407504B2 (ja) | 2012-09-21 | 2018-10-17 | アログ・ファーマシューティカルズ・インコーポレイテッドＡｒｏｇ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ，Ｉｎｃ． | 恒常的に活性であるリン酸化型ｆｌｔ３キナーゼの阻害方法 |
| US9603889B2 (en) | 2012-10-02 | 2017-03-28 | Bristol-Myers Squibb Company | IAP antagonists |
| TW201428002A (zh) | 2012-11-09 | 2014-07-16 | 必治妥美雅史谷比公司 | 用於抑制細胞凋亡抑制劑之巨環化合物 |
| WO2014100071A2 (en) | 2012-12-20 | 2014-06-26 | Merck Sharp & Dohme Corp. | Substituted pyrrolopyrimidines as hdm2 inhibitors |
| WO2014100065A1 (en) | 2012-12-20 | 2014-06-26 | Merck Sharp & Dohme Corp. | Substituted imidazopyridines as hdm2 inhibitors |
| EP2752191A1 (en) | 2013-01-07 | 2014-07-09 | Sanofi | Compositions and methods using hdm2 antagonist and mek inhibitor |
| GB201311910D0 (en) | 2013-07-03 | 2013-08-14 | Glaxosmithkline Ip Dev Ltd | Novel Compounds |
| NL2011274C2 (en) | 2013-08-06 | 2015-02-09 | Illumicare Ip B V 51 | Groundbreaking platform technology for specific binding to necrotic cells. |
| WO2014134201A1 (en) | 2013-02-28 | 2014-09-04 | Amgen Inc. | A benzoic acid derivative mdm2 inhibitor for the treatment of cancer |
| WO2014151863A1 (en) | 2013-03-14 | 2014-09-25 | Amgen Inc. | Heteroaryl acid morpholinone compounds as mdm2 inhibitors for the treatment of cancer |
| GB201311888D0 (en) | 2013-07-03 | 2013-08-14 | Glaxosmithkline Ip Dev Ltd | Novel compounds |
| GB201311891D0 (en) | 2013-07-03 | 2013-08-14 | Glaxosmithkline Ip Dev Ltd | Novel compound |
| WO2015006524A1 (en) | 2013-07-12 | 2015-01-15 | Bristol-Myers Squibb Company | Iap antagonists |
| US20150259288A1 (en) | 2014-03-14 | 2015-09-17 | City Of Hope | 5-bromo-indirubins |
| EP4649963A3 (en) | 2014-04-14 | 2026-05-13 | Arvinas Operations, Inc. | Imide-based modulators of proteolysis and associated methods of use |
| US20180228907A1 (en) | 2014-04-14 | 2018-08-16 | Arvinas, Inc. | Cereblon ligands and bifunctional compounds comprising the same |
| US20160058872A1 (en) | 2014-04-14 | 2016-03-03 | Arvinas, Inc. | Imide-based modulators of proteolysis and associated methods of use |
| TW201613916A (en) | 2014-06-03 | 2016-04-16 | Gilead Sciences Inc | TANK-binding kinase inhibitor compounds |
| US20160022642A1 (en) | 2014-07-25 | 2016-01-28 | Yale University | Compounds Useful for Promoting Protein Degradation and Methods Using Same |
| US10071164B2 (en) | 2014-08-11 | 2018-09-11 | Yale University | Estrogen-related receptor alpha based protac compounds and associated methods of use |
| US9694084B2 (en) | 2014-12-23 | 2017-07-04 | Dana-Farber Cancer Institute, Inc. | Methods to induce targeted protein degradation through bifunctional molecules |
| JP6815318B2 (ja) | 2014-12-23 | 2021-01-20 | ダナ−ファーバー キャンサー インスティテュート，インコーポレイテッド | 二官能性分子によって標的化タンパク質分解を誘導する方法 |
| JP6817962B2 (ja) | 2015-01-20 | 2021-01-20 | アルビナス・オペレーションズ・インコーポレイテッドＡｒｖｉｎａｓ Ｏｐｅｒａｔｉｏｎｓ， Ｉｎｃ． | ターゲティングされたアンドロゲン受容体分解のための化合物および方法 |
| US12312316B2 (en) | 2015-01-20 | 2025-05-27 | Arvinas Operations, Inc. | Compounds and methods for the targeted degradation of androgen receptor |
| GB201504314D0 (en) | 2015-03-13 | 2015-04-29 | Univ Dundee | Small molecules |
| AU2016232705C1 (en) | 2015-03-18 | 2021-06-17 | Arvinas, Inc. | Compounds and methods for the enhanced degradation of targeted proteins |
| GB201506872D0 (en) | 2015-04-22 | 2015-06-03 | Ge Oil & Gas Uk Ltd | Novel compounds |
| GB201506871D0 (en) | 2015-04-22 | 2015-06-03 | Glaxosmithkline Ip Dev Ltd | Novel compounds |
| CA2988414C (en) * | 2015-06-04 | 2023-09-26 | Arvinas, Inc. | Imide-based modulators of proteolysis and associated methods of use |
| WO2016197114A1 (en) | 2015-06-05 | 2016-12-08 | Arvinas, Inc. | Tank-binding kinase-1 protacs and associated methods of use |
| WO2017007612A1 (en) | 2015-07-07 | 2017-01-12 | Dana-Farber Cancer Institute, Inc. | Methods to induce targeted protein degradation through bifunctional molecules |
| EP3319944A4 (en) | 2015-07-10 | 2019-04-24 | Arvinas, Inc. | MDM2-BASED MODULATORS OF PROTEOLYSIS AND RELATED USE METHODS |
| CA2988436A1 (en) | 2015-07-13 | 2017-01-19 | Arvinas, Inc. | Alanine-based modulators of proteolysis and associated methods of use |
| CA2994969A1 (en) | 2015-08-06 | 2017-02-09 | Dana-Farber Cancer Institute, Inc. | Targeted protein degradation to attenuate adoptive t-cell therapy associated adverse inflammatory responses |
| WO2017024317A2 (en) | 2015-08-06 | 2017-02-09 | Dana-Farber Cancer Institute, Inc. | Methods to induce targeted protein degradation through bifunctional molecules |
| EP3337476A4 (en) | 2015-08-19 | 2019-09-04 | Arvinas, Inc. | Compounds and methods for the targeted degradation of bromodomain-containing proteins |
| GB201516243D0 (en) | 2015-09-14 | 2015-10-28 | Glaxosmithkline Ip Dev Ltd | Novel compounds |
| BR112018008918A8 (pt) * | 2015-11-02 | 2019-02-26 | Univ Yale | compostos de quimera proteólise dirigida e métodos para preparação e uso dos mesmos |
| CN109153644B (zh) | 2016-03-16 | 2022-10-21 | H·李·莫菲特癌症中心研究有限公司 | 用以增强效应t细胞功能的针对cereblon的小分子 |
| US20170281784A1 (en) | 2016-04-05 | 2017-10-05 | Arvinas, Inc. | Protein-protein interaction inducing technology |
| WO2017185036A1 (en) | 2016-04-22 | 2017-10-26 | Dana Farber Cancer Institute, Inc. | Bifunctional molecules for degradation of egfr and methods of use |
| CN121974842A (zh) | 2016-05-10 | 2026-05-05 | C4医药公司 | 用于靶蛋白降解的胺连接的c3-戊二酰亚胺降解决定子体 |
| US10646488B2 (en) | 2016-07-13 | 2020-05-12 | Araxes Pharma Llc | Conjugates of cereblon binding compounds and G12C mutant KRAS, HRAS or NRAS protein modulating compounds and methods of use thereof |
| EP3512842B1 (en) | 2016-09-15 | 2024-01-17 | Arvinas, Inc. | Indole derivatives as estrogen receptor degraders |
| SI3526202T1 (sl) | 2016-10-11 | 2025-04-30 | Arvinas Operations, Inc. | Spojine in postopki za ciljno razgradnjo androgenskih receptorjev |
| MX2019005007A (es) | 2016-11-01 | 2019-07-18 | Arvinas Inc | Protac dirigidos a la proteína tau y métodos asociados de uso. |
| AU2017363257B2 (en) | 2016-11-22 | 2021-08-19 | Dana-Farber Cancer Institute, Inc. | Degradation of protein kinases by conjugation of protein kinase inhibitors with E3 ligase ligand and methods of use |
| IL266842B (en) | 2016-12-01 | 2022-09-01 | Arvinas Operations Inc | History of tetrahydronaphthalene and tetrahydroisoquinoline as estrogen receptor antagonists |
| CN110753693A (zh) | 2016-12-23 | 2020-02-04 | 阿尔维纳斯运营股份有限公司 | Egfr蛋白水解靶向嵌合分子和相关使用方法 |
| US10806737B2 (en) | 2016-12-23 | 2020-10-20 | Arvinas Operations, Inc. | Compounds and methods for the targeted degradation of fetal liver kinase polypeptides |
| IL325835A (en) * | 2016-12-23 | 2026-03-01 | Univ Yale | Compounds and methods for the targeted degradation of rapidly accelerated fibrosarcoma polypeptides |
| US11191741B2 (en) | 2016-12-24 | 2021-12-07 | Arvinas Operations, Inc. | Compounds and methods for the targeted degradation of enhancer of zeste homolog 2 polypeptide |
| IL300417A (en) | 2017-01-26 | 2023-04-01 | Arvinas Operations Inc | Bifunctional benzothiophene compounds, preparations containing them and their use in therapy |
| IL319363A (en) | 2017-01-31 | 2025-05-01 | Arvinas Operations Inc | Cervalon ligands and bifunctional compounds containing them |
| EP4119552A1 (en) | 2017-02-08 | 2023-01-18 | Dana-Farber Cancer Institute, Inc. | Regulating chimeric antigen receptors |
| WO2018200981A1 (en) | 2017-04-28 | 2018-11-01 | Quartz Therapeutics, Inc. | Raf-degrading conjugate compounds |
-
2017
- 2017-12-22 IL IL325835A patent/IL325835A/en unknown
- 2017-12-22 WO PCT/US2017/068322 patent/WO2018119448A1/en not_active Ceased
- 2017-12-22 KR KR1020257024694A patent/KR20250117470A/ko active Pending
- 2017-12-22 BR BR112019012878-6A patent/BR112019012878A2/pt active Search and Examination
- 2017-12-22 KR KR1020197021537A patent/KR102564201B1/ko active Active
- 2017-12-22 EP EP17882647.5A patent/EP3558994A4/en active Pending
- 2017-12-22 IL IL304704A patent/IL304704B2/en unknown
- 2017-12-22 US US15/853,166 patent/US10723717B2/en active Active
- 2017-12-22 CN CN202311248251.7A patent/CN117510491A/zh active Pending
- 2017-12-22 AU AU2017382436A patent/AU2017382436C1/en active Active
- 2017-12-22 JP JP2019534245A patent/JP7679173B2/ja active Active
- 2017-12-22 CN CN201780087131.XA patent/CN110741004B/zh active Active
- 2017-12-22 CA CA3047784A patent/CA3047784A1/en active Pending
- 2017-12-22 KR KR1020237026280A patent/KR102839545B1/ko active Active
- 2017-12-22 IL IL294423A patent/IL294423B2/en unknown
- 2017-12-22 MX MX2019007649A patent/MX2019007649A/es unknown
-
2019
- 2019-06-17 IL IL267410A patent/IL267410A/en unknown
- 2019-06-21 MX MX2023009031A patent/MX2023009031A/es unknown
- 2019-07-23 CO CONC2019/0007894A patent/CO2019007894A2/es unknown
-
2021
- 2021-01-08 AU AU2021200099A patent/AU2021200099B2/en active Active
-
2023
- 2023-02-03 JP JP2023015526A patent/JP2023065395A/ja active Pending
-
2024
- 2024-10-16 JP JP2024180795A patent/JP2025016525A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP7679173B2 (ja) | Ｒａｆ（急速進行性線維肉腫）ポリペプチドの標的分解のための化合物および方法 | |
| KR102642203B1 (ko) | 급속 진행형 섬유육종 폴리펩티드의 표적화 분해를 위한 다중 고리 화합물 및 방법 | |
| US11986531B2 (en) | Compounds and methods for the targeted degradation of rapidly accelerated fibrosarcoma polypeptides | |
| AU2025275145A1 (en) | Cereblon ligands and bifunctional compounds comprising the same | |
| CN119019369A (zh) | 含有与bcl6靶向部分连接的e3泛素连接酶结合部分的双官能分子 | |
| JP2020505327A (ja) | Ｅｇｆｒタンパク質分解標的化キメラ分子およびその関連する使用方法 | |
| JP2020505327A5 (enExample) | ||
| JP2020506914A5 (enExample) | ||
| BR112017028394A2 (en) | compound, composition, and methods for inducing degradation of a target protein in a cell and for treating a diseased condition or a diseased condition. | |
| RU2830173C2 (ru) | Полициклические соединения и способы целенаправленной деградации полипептидов быстро ускоренной фибросаркомы | |
| RU2782458C2 (ru) | Соединения и способы нацеленного расщепления полипептидов быстропрогрессирующей фибросаркомы |